EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy

Frank M Gao, Kartik Kishore, Dinesh Pandey, Hossein Jahanabadi, Meg Stevens, Ashani Lecamwasam, Rinaldo Bellomo, Leonid Churilov, Elif I Ekinci iD

Diabetes, Obesity and Metabolism · 2025-11 · 27 (11) · 6367-6374

DOI: 10.1111/dom.70029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 11.08.2025. Verfasst von Frank M Gao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Austin Hospital, Melbourne, Australia. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Ketosis, Diabetic Ketoacidosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Australian Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The use and safety of sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) in hospital are controversial due to the risk of ketoacidosis. We aimed to describe rates of ketosis, ketoacidosis, and acidosis in patients with type 2 diabetes treated with in‐hospital SGLT2i use. Materials and methods Single‐centre retrospective cohort study of adult patients with type 2 diabetes admitted for >24 h. Rates of ketone testing, ketone levels, ketosis precipitants, and ketoacidosis and acidosis frequency were determined from examination of electronic medical records. Outcomes were described relative to the first dose of SGLT2i in hospital.

Results

There were 1511 patients who received SGLT2i at any stage of admission; of these, 777 (51.4%) had ketone levels checked. Peak ketone levels after the first dose of SGLT2i were >1 mmol/L in 12.6% and >3 mmol/L in 2.8%. Eleven out of 12 patients with ketones >3 mmol/L post‐SGLT2i had ketosis in the setting of a procedure or surgery, sepsis, reduced oral intake, or critical illness. No patient admitted with heart failure had a ketone level >2 mmol/L. Biochemical ketoacidosis occurred in 1.7% of SGLT2i users pre‐first dose of SGLT2i and 0.7% after the first dose. Acidosis (irrespective of ketone levels) occurred in 16.8% before the first dose of SGLT2i and 5.5% after the first dose.

Conclusions

Ketosis following inpatient SGLT2i administration was infrequent and generally occurred in the setting of known precipitants. These results suggest that, in hospitalized patients selected by clinicians to receive SGLT2i, clinically significant ketone accumulation is low in prevalence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2KetosisDiabetic KetoacidosisHypoglycemic AgentsHumansRetrospective StudiesMaleFemaleMiddle AgedHospitalizationAgedAdultKetones

Stichwörter der Autor:innen

SGLT2 inhibitorsdiabetic ketoacidosisheart failurehospitalizationketosistype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsKetonesHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Endocrinology, Austin Hospital, Melbourne, Australia.
  • Department of Medicine, Austin Health, Melbourne Medical School, The University of Melbourne, Melbourne, Australia.
  • Australian Centre for Accelerating Diabetes Innovations, Melbourne Medical School, The University of Melbourne, Melbourne, Australia.
  • Data Analytics Research and Evaluation Centre, Austin Hospital, Melbourne, Victoria, Australia.
  • Department of Nephrology, Northern Health, Melbourne, Australia.
  • Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

ORCID-Profile: Elif I Ekinci

Förderung

  • Australian Government

Zitieren

APA

Gao, F. M., Kishore, K., Pandey, D., Jahanabadi, H., Stevens, M., Lecamwasam, A., Bellomo, R., Churilov, L., & Ekinci, E. I. (2025). Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy. Diabetes, Obesity and Metabolism, 27(11), 6367-6374. https://doi.org/10.1111/dom.70029

Vancouver

Gao FM, Kishore K, Pandey D, Jahanabadi H, Stevens M, Lecamwasam A, et al. Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy. Diabetes, Obesity and Metabolism. 2025;27(11):6367-6374. doi:10.1111/dom.70029

BibTeX
@article{Gao2025,
  author = {Gao, Frank M and Kishore, Kartik and Pandey, Dinesh and Jahanabadi, Hossein and Stevens, Meg and Lecamwasam, Ashani and Bellomo, Rinaldo and Churilov, Leonid and Ekinci, Elif I},
  title = {Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {11},
  pages = {6367--6374},
  doi = {10.1111/dom.70029}
}
Kostenlos starten →